Cancer Cachexia Drug Market - Strategic Insights and Forecasts (2026-2031)

Market growth is primarily driven by the rising prevalence of advanced cancers, increasing focus on supportive oncology care, growing awareness of muscle preservation outcomes, and expanding research into metabolic and anti-inflammatory therapies.

Cancer cachexia negatively impacts treatment tolerance, reduces patient mobility and quality of life, increases hospitalization risk, and contributes significantly to cancer-related mortality.

Cachexia is highly prevalent in patients with pancreatic, lung, gastric, and colorectal cancers.

Muscle wasting and nutritional decline reduce a patient’s ability to tolerate chemotherapy, radiation therapy, immunotherapy, and other cancer treatments, often leading to treatment interruptions.

Key challenges include lack of standardized clinical endpoints, delayed diagnosis, inconsistent reimbursement policies, and limited survival evidence for some therapies.